{"entity":{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","aka":[],"tldr":"Health workers with a torch and vinegar, screening women in Mumbai's slums every two years, cut cervical cancer deaths by 31% in a trial of more than 150,000 women.","summary":"75,360 women in ten screening clusters and 76,178 in ten control clusters were enrolled; screening participation was 89% and compliance with diagnostic confirmation 79.4%. Invasive cervical cancer incidence was similar (26.74 versus 27.49 per 100,000) but cervical cancer mortality fell by 31% (rate ratio 0.69; 95% CI 0.54-0.88; P=0.003), with better treatment completion in the screened group (86.3% versus 72.3%). The authors estimated that this approach could prevent about 22,000 cervical cancer deaths a year in India. Together with Osmanabad it shaped India's operational guidelines for population screening where HPV testing is not yet affordable.","status":"positive","asOf":"2026-09-10","links":[{"label":"Shastri et al., JNCI 2014","url":"https://doi.org/10.1093/jnci/dju009"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-testing","colposcopy-excision"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":["osmanabad-hpv-screening"],"people":["shastri-surendra"],"bottlenecks":["b-early-detection","b-workforce","b-global-access"],"keyPapers":["paper-shastri-j-natl-cancer-inst"],"journals":[],"dependsOn":[],"notes":[],"phase":"3","setting":"Cluster-randomised trial in 20 slum clusters of Mumbai: visual inspection with acetic acid by trained primary health workers every 2 years vs health education, women aged 35-64","sponsor":"Tata Memorial Centre","result":"Cervical cancer mortality rate ratio 0.69 (31% reduction).","yearReported":2014,"enrolled":151538,"enrolledBasis":"registry","outcomes":[{"endpoint":"Cervical cancer mortality (rate ratio)","primary":true,"arms":[{"name":"VIA screening by health workers","n":75360,"value":0.69,"note":"Rate ratio vs control; 95% CI 0.54-0.88"}],"p":"0.003","source":"https://doi.org/10.1093/jnci/dju009"}]},"route":"/trials/mumbai-via-screening/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/"},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/"},{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/"}],"institution":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"trial":[{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/"}],"person":[{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"paper":[{"id":"paper-shastri-j-natl-cancer-inst","kind":"paper","name":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","route":"/key-papers/paper-shastri-j-natl-cancer-inst/"}],"term":[{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}